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Abstract Identifying disease-causing mutations in DNA
has long been the goal of genetic medicine. In the last
decade, the toolkit for discovering DNA variants has
undergone rapid evolution: mutations that were historically
discovered by analog approaches like Sanger sequencing
and multiplex ligation-dependent probe amplification
(‘‘MLPA’’) can now be decoded from a digital signal with
next-generation sequencing (‘‘NGS’’). Given the explosive
growth of NGS-based tests in the clinic, it is of the utmost
importance that medical practitioners have a fundamental
understanding of the newest NGS methodologies. To that
end, here we provide a very basic overview of how NGS
works, with particular emphasis on the close resemblance
between the underlying chemistry of Sanger sequencing
and NGS. Using a pair of simple analogies, we develop an
intuitive framework for understanding how high-confi-
dence detection of single-nucleotide polymorphisms,
indels, and large deletions/duplications is possible with
NGS alone.
Keywords Next-generation sequencing (NGS)  Variant
calling  SNP/indel calling  Del/dup calling  Read depth
Introduction
Assembly of the first human genome sequence consumed
12 years and cost nearly $3 billion [1, 2••, 3, 4]. The effort
involved hundreds of researchers around the world and was
a tour de force of the ‘‘first-generation’’ Sanger sequencing
technology developed in the 1970s. Unfortunately, by the
end of the Human Genome Project in 2002, this mature
sequencing technique was already operating at nearly peak
efficiency, making it totally unsuitable for scaling up to the
task of sequencing millions of patients’ genomes quickly
and affordably. Therefore, in order for the theoretical
promise of personalized genomic medicine to become a
clinical reality, a quantum leap in sequencing technology
was required.
Remarkably, not even 15 years after decoding the first
human genome, NGS techniques [5] now enable the
sequencing of an entire human genome in a single day for
around $1000. These advances have allowed NGS-based
tests to enter the clinic, where they are an exponentially
growing presence in carrier screening [6••], testing for fetal
aneuploidies [7, 8, 9•], detecting the presence of rare dis-
eases [10], and assessing both the risk and existence of
cancer [11, 12••]. The clinical utility of an NGS-based test
stems from its ability to confidently identify the differences
between a patient’s genome and the reference genome.
Such genomic differences—called ‘‘variants’’—fall into
two classes: (1) changes to the DNA sequence, e.g., the
single-nucleotide polymorphisms (‘‘SNPs’’) and short
insertions/deletions (‘‘indels’’) in the CFTR gene that can
cause cystic fibrosis [13], and (2) large deletions/duplica-
tions (‘‘del/dups’’, a.k.a., ‘‘copy-number variations’’ or
‘‘CNVs’’), e.g., the whole-gene deletions of HBA1 and
HBA2 that largely determine the presence and severity of
alpha-thalassemia [14]. Here we discuss how NGS is
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exquisitely capable of revealing both types of variants in
patients’ genomes.
How Does NGS Work?
The term ‘‘NGS’’ does not denote a single technique;
rather, it refers to a diverse collection of post-Sanger
sequencing technologies developed in the last decade.
These innovations include sequencing-by-synthesis [15],
sequencing-by-ligation [16], ion semiconductor sequencing
[17], and others. However, because the predominant tech-
nique used in genetic medicine today is the sequencing-by-
synthesis approach employed by Illumina devices, here we
use the term NGS to refer specifically to Illumina-style
sequencing.
Even though NGS is largely displacing Sanger
sequencing in molecular diagnostics [18, 19], the two
technologies share a common origin that dates back mil-
lions of years: both repurpose the DNA replication
machinery that copies DNA during every cell division. In a
conceptually simplified form, DNA replication requires
only three types of molecules: a template strand, free bases,
and a polymerase enzyme that links the free bases together
one-at-a-time into a new strand complementary to the
template (Fig. 1, top).
The key innovation that transforms DNA replication
into the DNA-sequencing strategy at the core of both
Sanger and NGS is the use of unextendable, fluorescently
labeled modified bases. There are four different colors of
modified bases for A, T, G, and C (Fig. 1, top). In Sanger
sequencing, only a small percentage of bases are modified,
whereas in NGS, all available bases are modified. In both
sequencing techniques, when polymerase incorporates a
modified base into the copied strand, extension of the new
strand stops, and, critically, this newly terminated strand is
uniquely colored to reflect its most recently added base.
The fundamental challenge for the sequencer, then, is to
organize molecules such that their fluorescence signal is
interpretable. In Sanger sequencing, an ensemble of DNA
molecules—all originating from the same position on the
template but having different size due to termination at
different positions—are arranged in an electric field, which
separates them by size because DNA is negatively charged
[20•]. As the molecules migrate in the presence of the
electric field, they flow past a detector that registers the
fluorescence intensity and color, yielding a series of peaks
that can be mapped directly to a DNA sequence.
Rather than exploit size separation to arrange the fluo-
rescent molecules, NGS uses positional separation: mil-
lions of different template DNA strands bind to discrete
positions on a glass slide and remain fixed at the same
position throughout the entire sequencing reaction. Each
template is then extended by a single modified base, and a
microscope captures an image that resolves both the posi-
tion of each template on the glass as well as its fluorescent
color and intensity (for clarity, an amplification step is
omitted from Fig. 1 whereby each template is copied
nearby on the glass slide such that fluorescence signal is
amplified). Next, in a step unique to NGS, the modified
bases are converted to regular bases, such that they become
both extendable and non-fluorescent. This restoration pro-
cess primes them to undergo subsequent rounds of single-
base extension and imaging. At the end of a sequencing run
with n imaging cycles, the fluorescence color at each
template position in each image is mapped to a base (i.e.,
A, T, C, or G). The bases from a single template position
are concatenated to yield a DNA sequence of length n,
called a ‘‘read.’’ Interestingly, although initial NGS read
lengths were\100 and trailed behind Sanger’s typical 400-
to 500-base sequences, newer NGS machines can match or
exceed the length of Sanger-generated sequences.
Our discussion thus far illustrates that both NGS and
Sanger are extremely similar in that they perform a few
basic and common steps: extension of DNA molecules one
base at a time in the presence of modified bases, arrange-
ment of those molecules (either by size in Sanger or by
location with NGS), and detection of fluorescence. The two
techniques are distinguished, however, by the order of
these steps and the inclusion of the restoration step in NGS.
Although these differences are subtle, they have a
tremendous impact on throughput. While a Sanger reaction
returns a single DNA sequence, a typical NGS experiment
can yield more than 250 million unique reads. To gain
some perspective on this huge number, consider that 100
Sanger sequencers running around the clock would need
about 3.5 years to sequence the human genome, whereas a
single NGS machine can do the same in a little more than
one day.
How Does NGS Allow Confident SNP and Indel
Identification?
Although NGS yields a staggering amount of sequencing
data, its ability to transform genetic medicine relies on
identifying clinically relevant variants with high confi-
dence. Variant identification begins with alignment of NGS
reads to the human genome reference sequence [21],
depicted in Fig. 2. Although there are three billion bases in
the human genome, reads of length C25 are typically
sufficient for unique alignment, even allowing for mis-
matches or gaps. The number of reads that align at a given
position is called the ‘‘depth’’ or ‘‘coverage.’’ Variants are
simply deviations from the reference sequence. For
instance, heterozygous SNPs (Fig. 2a, red) manifest as
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positions where approximately half of the reads match the
reference, and the other reads differ from the reference.
Indels shorter than the read length are similarly conspicu-
ous, with a nearly 50/50 split between reference reads and
gapped reads.
A recurrent source of confusion in the field is how much
depth is required to make confident SNP and indel calls.
For instance, is 59 depth enough? Is 509 needed? Does
10009 depth give much better performance than 1009?
To give insight into these questions, we use an analogy
in which coins represent genotypes. Suppose we have three
coins: one has two heads, one has a head and a tail, and one
has two tails. Imagine that a referee picks a single coin,
repeatedly flips it while announcing heads or tails, and,
after a number of flips, asks you to say which coin was
selected. To make the game slightly more challenging,
suppose the referee lies 1 % of the time and reports heads
when the coin lands on tails, and vice versa. This scenario
is highly analogous to the challenge of variant identifica-
tion from NGS data: each of the three coins is a possible
genotype (two heads is ‘‘homozygous reference,’’ a head
and a tail is ‘‘heterozygous,’’ and two tails is ‘‘homozygous
Fig. 1 NGS is a slightly
modified, digital, and vastly
scaled-up implementation of
Sanger sequencing. In both
methodologies, a polymerase
copies template molecules by
incorporating nucleotides from
a pool, that is, either partially
(Sanger) or entirely (NGS)
composed of dyed and
unextendable bases. Extension,
arrangement, and detection are
shared steps in both protocols
but occur in different order,
with NGS alone having a
restoration step that converts
bases to the undyed and
extendable form
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alternate,’’ see Fig. 2b), each coin flip is one read, the
sequencer makes mistakes *1 % of the time, and saying
which coin the referee selected is the same as calling the
genotype. Figure 2b shows how the respective probabilities
of each coin change with the number of flips, assuming the
coins model a site with a minor allele frequency of 50 %.
Before any flips have occurred, the probability of a
heterozygous coin is 50 %, and the respective probabilities
of the two homozygous coins are 25 %. However, the
probabilities shift dramatically with only a few flips of the
coin.
How many coin flips do you need to confidently call the
identity of the coin? Clearly two flips are too few: for
instance, after two heads (Fig. 2b-i), there is still a nearly
20 % chance of a heads–tails coin. Even the observation of a
heads and a tails is insufficient to conclude a heads–tails coin,
since the nonzero rate with which the referee lies means that
there is still a 1 in 27 chance of the coin being heads–heads
(Fig. 2b-ii) rather than heads–tails (Fig. 2b-iii).
Although two flips are obviously insufficient, with only
20 flips it is possible to achieve a remarkable 99.9999 %
confidence in the coin’s identity; put differently, the chance
of being wrong with 20 flips is less than one in a million.
As expected, the chances of being wrong continue to drop
with more coin flips. In fact, with 50 heads and no tails, the
chance of the coin not being a heads–heads coin is 1 in
1015, which means that every person on Earth would call
nearly 150,000 coin identities correctly before even one
coin is miscalled.
The coin-flipping analogy casts important light on
interpreting both data and marketing materials from NGS-
based tests: since a SNP call is all but certain at 509 depth,
extremely high read depth has an arguably bigger effect on
increasing the cost of a test than improving its clinical
performance.
Indeed, Fig. 2c shows that in an NGS test with 1009
average depth, the vast majority of sites have[509 depth,
which allows the test to generate conspicuously obvious
and statistically significant genotype calls with extremely
low error rates. The figure further shows that despite an
average depth of 1009, the depth at many sites differs
considerably from the average value, raising the question
of which metric—average or minimum depth—is the best
indicator of a test’s variant-call confidence. We revisit the
coin analogy to gain insight: Suppose you have to correctly
identify three different coins in succession and can select
either an average of 50 flips per coin or a minimum of 20
flips per coin. Remarkably, the minimum of 20 flips is
easily the best option here, since an unscrupulous referee
could achieve an average of 50 by flipping the first coin
148 times and the other two coins only once each. Indeed,
since read depth is not constant across all sites in NGS data
(Fig. 2c), we suggest that minimum depth—not average
depth—is the most direct and informative metric for
assessing the confidence in a test’s variant calls.
One last important point about identifying short variants
like SNPs and indels is that sequencer error is not uniform at
all sites. Indeed, the NGSmachine generallymakes mistakes
only 0.1 % of the time [22], but there are rare sites where the
sequencer is systematically more error prone (e.g., *1 %
error rate). At these sites, the sequencer behaves like a referee
who lies pathologically about coin-flip outcomes. Increasing
the number of coin flips alone may not solve the problem,
since each new result could still be a lie; similarly, increased
sequencing depth alone may not yield good calls at sites
corrupted by systematic error. However, you could outsmart
the referee by having him repeatedly flip double-headed
coins: If he reports back tails more often than the expected
rate of random error, he is a liar. In an NGS context, this
approach entails measuring thousands of reads at every site
from reference samples that have well-established geno-
types; sites with reproducibly elevated non-reference read
counts, therefore, can be flagged for special handling (e.g.,
assessing the site with a different assay if the NGS errors
prohibit sufficient call confidence).
How are Large Deletions/Duplications Revealed
from NGS Data?
Disease-causing mutations span a range of lengths: SNPs
affect single bases and indels usually affect fewer than five
bases, but del/dups can span hundreds to many thousands
of bases. Unlike SNPs and indels—which are far shorter
than NGS reads and thus are conspicuous within single
reads—del/dups can far exceed an NGS read length.
Nevertheless, del/dups can still be confidently identified
from NGS data with the proper analysis strategy.
bFig. 2 High-confidence SNP and indel calls possible from NGS data
with[209 depth. a SNPs and indels are conspicuous from NGS data
after the reads (gray; each read is 28 bases long) are aligned to the
reference genome (excerpted in black), and the confidence of each
call depends on the depth at that position. b The three potential
genotypes for a simple diploid variant are represented as different
types of coins (top). A referee who lies about the coin-flip outcome
1 % of the time reports the results of 20 successive flips for three
different coins (i–iii); the probability that the referee selected each
type of coin is indicated after 2, 5, 10, and 20 flips, with the coin at
right being the one with maximum probability. The probabilities
indicated before the coin is flipped assume the coins model a genomic
variant with 50 % minor allele frequency (‘‘MAF’’). c (i) Call
confidence as a function of respective read depth for reference and
alternate bases is shown, where gray regions have confidence
\99.9999 %, and the three-colored regions have [99.9999 %
confidence in homozygous reference (red), heterozygous (green),
and homozygous alternate (yellow) calls. (ii) Each point shows the
reference-versus-alternate read depth across sites with MAF C45 %
in a typical targeted NGS experiment
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To underscore the ability of NGS to call del/dups, we
compare it to one of the current standards for clinical del/
dup detection: multiplex ligation-dependent probe ampli-
fication (MLPA) [23]. Just as NGS has strong conceptual
parallels with Sanger sequencing, NGS calling of del/dups
has much in common with MLPA. In a single MLPA
experiment, the copy number of *40 locations in the
genome can be assessed. Each location is bound by a probe
whose length is specific to that location (Fig. 3a). Probes
that successfully bind to genomic DNA are competent for
amplification, thus the amount of amplified probe is pro-
portional to the amount of genomic DNA (i.e., a deletion
that halves the amount of genomic DNA will yield half as
much amplified probe). Probes are fluorescently labeled,
separated by size in an electric field, and measured with a
fluorescence detector using the same instrument employed
for Sanger sequencing. A duplication or deletion in MLPA
manifests as one or more genomic locations—each with a
different peak in the MLPA data profile—having 50 %
more or less of the expected probe abundance, respectively.
The above description of MLPA can effectively be
summarized as follows: it measures the abundance of
genomic DNA at a handful of locations. By comparison,
because NGS inherently measures the abundance of DNA
at millions of locations in the genome—where abundance
is simply the read depth—it is particularly well suited to
calling del/dups anywhere in the genome. Beyond its
ability to probe far more sites, NGS is also superior to
MLPA in its ability to identify del/dup junctions—e.g.,
between regions 1 and 3 in the deletion allele in Fig. 3a—
which provide extremely compelling evidence for a large
rearrangement. Although MLPA can measure a handful of
Fig. 3 Del/dup calling from NGS data requires simple and intuitive
processing of raw data. a Schematic of MLPA (top) and NGS
(bottom) data for a sample in which one chromosome is normal and
the other has a deletion. MLPA probes have a genome-binding
sequence (shades of green), stuffer sequence to give them unique
length (black), and binding sites for common primers (red) at the
termini that enable multiplex amplification. For NGS, read depth can
be pooled across a region (as depicted) or counted at a single site. In
addition to depth data supporting a del/dup, NGS provides evidence
of junction reads that further support the observation of a del/dup. For
clarity, the ligation step that fuses two DNA fragments into the probes
depicted in the figure is omitted. b A chocolate store that underper-
forms relative to others is revealed by dividing (i) the hypothetical
annual sales volume for each store by its average (yielding ii) and
then dividing once more by the monthly average across stores (giving
iii). cMultiple samples with del/dups in the HBA locus are discovered
by normalizing (i) the raw depth data across many sites by the sample
average and then by the site average (yielding ii, where del/dup
samples have thick traces)
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hypothesized junctions with custom probes, an NGS
experiment needs no special treatment to yield junction
reads and thus could identify del/dup interfaces anywhere
in the genome.
Unlike SNP and indel calling—where the raw reads
themselves reveal a mutation—del/dup detection using
NGS requires numerical processing of the data before the
variants become conspicuous. We again use an analogy to
provide intuition for the approach. Suppose you are the
new regional manager for a chocolate-retail company. You
want to find which stores have had deflated sales numbers
for a sustained period, so that you can best deploy
resources to help them.
Figure 3b-i shows last year’s raw sales numbers by
month for the 15 stores in your region. A few important
features are clear from this plot: (1) stores with high
sales—perhaps those in choice locations with lots of
chocolate enthusiasts—tend to have high sales across each
month, (2) all chocolate stores have spiky sales, with
expected peaks in December for the holidays and in
February for Valentine’s Day, and (3) it is nearly impos-
sible to tell from this plot which stores, if any, are under-
performing. Fortunately, you can resolve the last point by
addressing the first two in turn.
To account for the fact that some stores have higher
baseline sales than other stores, divide each store’s monthly
sales by its yearly average, yielding Fig. 3b-ii. Now all
stores are operating from the same effective baseline, but it
is still not obvious which store is struggling due to the
monthly sales spikes. Thus, to mitigate the monthly sales
spikes that affect all stores, calculate the average adjusted
sales across stores for each month (e.g., February’s adjus-
ted average is 3), and divide all adjusted sales numbers by
their corresponding monthly average (i.e., divide all stores’
February sales by 3). This second step yields the data in
Fig. 3b-iii, where the struggling store is readily apparent.
This chocolate-store example has very strong similari-
ties with del/dup analysis from NGS data. The chocolate
analogy applied two simple normalizations to bulk sales
data collected across many stores and many months to
reveal a single store with depleted sales. By comparison,
because depth in most NGS applications is proportional to
the relative copy number of DNA in a region, the same two
normalizations can be applied to depth data across many
samples and many sites to discover a sample with a del/
dup. Figure 3c-i shows raw NGS data for 96 samples
across 60 sites in the HBA region on chromosome 16 that
can cause alpha-thalassemia when gene copy number is
disrupted [14] (note that since del/dup detection depends
on relative changes in read depth, it is useful to have C509
minimum depth in such regions). There are eight carrier
samples and three affected samples in the plot, yet none are
apparent from the raw data. Some samples have a higher
baseline because their DNA was more efficiently amplified,
and some probes perform better than others at capturing
DNA for sequencing. However, by applying the chocolate-
store approach of normalizing by each sample’s baseline
depth and then normalizing again by each site’s adjusted
average, we generate a plot (Fig. 3c-ii) in which the sam-
ples with del/dups are easily and confidently identified.
Conclusion
In this report, we have described how NGS data are col-
lected and analyzed. We showed that the mechanism of
NGS is not a fundamental departure from its predecessor,
but rather an improved and scaled version of Sanger
sequencing that allows for a staggering increase in data
quality and throughput. We argue that minimum depth is a
better reflection of a test’s variant-call confidence than
average depth, and demonstrate that SNPs, indels, and del/
dups can be confidently identified using intuitive analysis
techniques. Our primary hope is that we can make NGS-
based genetic tests more accessible to patients by making
the inner workings of the technology itself more accessible
to practitioners of genetic medicine.
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